CRISPR-mediated Nr2f6 ablation in combination with PD-L1 blockade in tumors resistant to anti-PD-L1 monotherapy has been able to increase IFN-γ secretion and delay tumor growth, suggesting a synergistic effect [88]. Here, NR2F6 is linked to neoplasm.